Melanotan 2 in Australia: a melanocortin-receptor research guide

Melanotan 2 in Australia. Melanotan II (MT-2) is a synthetic cyclic analogue of α-melanocyte-stimulating hormone (α-MSH) referenced across the melanocortin-receptor research literature. It is studied in vitro as a research tool for probing the melanocortin system — the family of five G-protein- coupled receptors (MC1R through MC5R) through which the endogenous melanocortin peptides signal. This guide is a research-reference summary for Australian researchers: what the compound is, where it sits in the literature, and how research-grade material is verified. It makes no medical, cosmetic, or human-use claim.

The melanocortin system in research

The melanocortin receptors are a family of five class-A GPCRs — MC1R, MC2R, MC3R, MC4R and MC5R — that respond to the melanocortin peptides derived from pro-opiomelanocortin (POMC), including α-MSH. Each receptor has a distinct research profile: MC1R is studied in melanocyte and pigment-cell biology research, MC2R in adrenal-signalling research, and MC3R/MC4R in central melanocortin-pathway research. Because the endogenous agonists are short-lived, stabilised synthetic analogues such as Melanotan II are used as research tools to interrogate melanocortin-receptor pharmacology in controlled laboratory models.

Where Melanotan II sits in the literature

Melanotan II is referenced as a broad, non-selective melanocortin-receptor agonist — active across MC1R, MC3R, MC4R and MC5R in research models. Structurally it is a cyclic lactam heptapeptide analogue of the α-MSH core sequence, engineered for greater in-vitro stability than the native hormone. That broad receptor activity is precisely why it is studied as a reference agonist when researchers characterise melanocortin- receptor signalling, compare receptor subtype responses, or benchmark newer, more subtype-selective analogues against a known wide-spectrum tool compound.

It is most usefully understood alongside its more selective counterpart. Where Melanotan II is broad- spectrum, PT-141 (bremelanotide) — a metabolite in the same structural family — is studied as a more MC4R-focused agonist. Researchers comparing melanocortin-subtype behaviour frequently reference the two together; see the PT-141 product page for the MC4R-focused research compound.

Identity, purity and the COA moat

In research peptides, the compound is only as useful as its verified identity and purity — a mislabelled or impure vial invalidates the work. Every batch of Melanotan II supplied by Elite AU Peptides is independently HPLC-tested by Janoshik before it is listed. The measured purity is published on the Melanotan II product page and in the lab-reports library — a real batch number, the measured percentage rather than a marketing figure, and a report you can verify independently at janoshik.com. Nothing is listed without a certificate on file.

Reconstitution and handling for research use

Melanotan II ships as a lyophilised (freeze-dried) powder. For laboratory handling it is reconstituted with bacteriostatic water; the volume depends on the working concentration a given protocol requires. Store the lyophilised powder at −20°C; once reconstituted, refrigerate at 2–8°C and use within the documented research window. The batch label is the canonical reference for the certificate of analysis in the lab-reports library, so keep vials in their tamper-evident packaging until use and record batch numbers in your protocol notes.

Compliance and research-use framing

Melanotan II is not TGA-approved, is not a therapeutic good, and is not a cosmetic product. Elite AU Peptides supplies it strictly for in-vitro and laboratory research use only — not for human or animal consumption. We make no medical, cosmetic, or human-use claim about this compound; the material above is a research-reference summary of the published melanocortin-receptor literature, not guidance for any use. Researchers should consult primary peer-reviewed sources for receptor-binding affinities, assay conditions, and protocol- specific reference values, and are responsible for the regulatory and institutional requirements that apply to their work.